Zhi-Hong Jiang) 16 2 † These authors contributed equally to this work. 17 18 3 Plants containing countless chemical constituent have benefited mankind since 19 the origin of life. Although secondary metabolites in plants, such as morphine, 20 artemisinin and taxol, have been developed as therapeutic drugs for clinical 21 therapy, few study focuses on the pharmacological activities of plant small RNAs 22 with function of cross-kingdom regulations. Yew is widely considered as a 23 "superstar" plant due to the discovery of paclitaxel, or taxol, which is a 24 well-known natural drug for the treatment of multiple types of cancer 1 . Here we 25 show the surprising finding that an RNA fragment, named tRF-T11, derived 26 from tRNA His(GUG) of Chinese yew strongly suppressed human ovarian cancer 27 progression. In A2780 cells, tRF-T11 mimic (a double-stranded RNA with 28 tRF-T11 as antisense chain) exhibited potent cytotoxicity comparable to that of 29 taxol, but no significant cytotoxicity to normal ovarian surface epithelial cells. 30 Moreover, the cytotoxicity of tRF-T11 mimic is 80-fold stronger than that of 31 taxol in taxol-resistant A2780 cells. Bioinformatic and molecular biological 32 studies revealed that tRF-T11 targets transient receptor potential cation channel 33 subfamily A member 1 (TRPA1) to inhibit its expression levels. In a further in 34 4 vivo investigation, the growth rate of ovarian tumor xenografts in nude mice was 35 significantly reduced by treatment with tRF-T11 mimic, and the TRPA1 protein 36 expression in tumors treated with tRF-T11 mimic was also down-regulated. Our 37 findings are the first to provide evidence that plant-derived tRFs can regulate 38 the expression of target genes in vitro and in vivo, indicating that they may 39 become as a new source of druggable siRNA. Moreover, this discovery 40 demonstrated a pilot example of an innovative approach for not only identifying 41 pharmacologically-active tRFs from plants, but also for improving the efficiency 42 and possibilities of discovering new drug target. 43
have been identified as active compounds. Intriguingly, crude plant extracts were 48 more effective than the synthetic versions of phytochemicals, implying that whole 49 plant extracts contain a cocktail of products in which substances like macromolecules 50 5 other than small molecules may contribute to the overall pharmacological effects 2 . 51 However, few study has been performed on the pharmacological activity of plant 52 macromolecules excluding polysaccharides because they are considered inactive, 53 nonabsorbable and unstable in human body, such as RNA, DNA and proteins. Small 54 RNAs (<200 nt) were found to play critical roles in a wide range of biological 55 processes in microorganisms, plants, animals and human, and to participate in a 56 variety of human diseases by regulating protein-coding genes 3, 4 . Since the first 57 evidence that plant-derived miRNAs can regulate gene expression in mammalian 58 systems was provided by Zhang et al 5 in 2012, many other miRNAs from small RNAs 59 in plants have been extensively studied for their cross-kingdom regulatories 6-9 . These 60 findings suggested the promise of small RNAs from plants to be developed as 61 therapeutic agents. A recent report by Shekhawat 10 showed that the small RNA of 62 corn exhibited appreciable antiproliferative activity toward HeLa cells, implying the 63 possibility that small RNA species with larger molecular weight than miRNA play 64 regulatory roles. In fact, as the most abundant small RNA species expressed in all 65 living organisms, transfer RNAs (tRNAs) play a well-defined role in protein 66 6 translation and perform diverse regulatory functions in some important biological 67 processes, such as cell signaling, apoptosis modulation and stress response programs 11 . 68
Recently, tRNA-derived fragments (tRFs) have also been recognized to play 69 regulatory roles 12 . This class of small RNAs is non-randomly generated from tRNAs, 70 and many are specifically and abundantly produced under particular conditions, such 71 as cancer and viral infection 13, 14 . Some studies have also revealed that the expression 72 of several tRFs is positively correlated with cell proliferation in different cancer cell 73 lines 15 , suggesting that tRFs and their related signaling pathways could be novel 74 targets for intervention in the treatment of cancers. These findings prompted us to 75 consider the further possibility that in addition to well-established players such as 76 miRNAs and small molecules in plants, tRNAs and their fragments, which account 77 for overwhelming majority of small RNA species in plants, may hold great potential 78 as biological regulators in mammals. Below, we describe the first study of the 79 pharmacological activities of tRNAs and tRFs derived from Chinese yew (Taxus 80 chinensis) and identification of their molecular target. 81 7 Total RNA with high integrity (RIN=7.7) and purity (A260/280=2.08, 82 A260/230=2.00; Supplementary Fig 1a) was isolated from fresh branches of T. 83 chinensis by using a well-developed CTAB method ( Supplementary Fig 1b, c) , in 84 which small RNA was separated from large RNA with high purity (<200 nt, 85 Supplementary Fig 2) . The tRNAs were then gel fractionated and purified 86 ( Supplementary Fig 3a) to successfully delete 5S and 5.8S rRNA and other RNA 87 species ( Supplementary Fig 3b) . Sequence information and the proportion of each 88 type of RNA in this tRNA-enriched fraction (tEF) were determined by performing 89 next-generation sequencing (NGS). As shown in Fig 1c and Supplementary Table 1 , 90 over 1.7 million clean reads distributed mainly from 60 to 80 mer were generated, and 91 over 20 individual tRNA sequences were identified, which accounted for 92 approximately 14% of the overall number of reads in the tEF library (Fig 1d) . The 93 cytotoxicity of the tEF was investigated using an MTT assay on the A2780 human 94 ovarian cancer (OVCA) cell line. The IC 50 value for dose-dependent growth 95 inhibition of A2780 cells in vitro was 128.8 nM when the tEF was well encapsulated 96 and delivered via liposomes, while no significant cytotoxicity of the tEF was observed 97 without transfection (Fig 1a, b ), implying that tRNAs or their fragments in the tEF 98 might act as effectors. Furthermore, when rRNA degradation fragments (Fig 1e) were 99 removed from the tEF samples via a Ribo-Zero rRNA removal kit (Illumina), the 100 retained tRNA species induced the death of A2780 cells with increased efficiency 101 HepG2 of liver cancer and MCF-7 of breast cancer cells. As a result, A2780 and 108 HepG2 cells exhibited a proliferation reduction of over 75% when treated with 109 individual tRNAs at 25 nM (Fig 1j, k) , while MCF-7 cells were much less sensitive 110 (reduction of less than 30%) to these tRNA molecules. This pattern corresponded to 111 an approximate IC 50 value of 14.3 nM for the growth inhibition of A2780 cells caused 112 9 as a positive control drug (Fig 1l) . This provides the first evidence of pharmacological 114 activities of plant-derived tRNAs, suggesting that they are a new class of therapeutic 115 agents from medicinal plants. 116
Meanwhile, since the previous study has revealed that the tRFs could regulate 117 endogenous gene in breast cancer cells 15 , we hypothesized that tRF from the above 118 cytotoxic tRNAs of Chinese yew may be pharmacologically-active. Indeed, tRFs 119 from the 5' terminal and 3' ends (5'-tRF and 3'-tRF, respectively) are the most 120 abundant tRFs associated with the AGO protein, which is a key component of the 121 RNA interference pathway 17 . A similar report showed that a 5'-tRF of 19 nucleotides 122 is the most abundant tRF in land plants 18 . Thus, 36 tRFs derived from the top 9 123 abundant tRNAs of Chinese yew, including 5'-tRF and 3'-tRF with lengths of 22 and 124 19 nt, respectively, were selected as antisense strands of tRF mimics in siRNA form 125 (Fig 2a, Supplementary Table 2 ), and the antiproliferative activities of these tRF 126 mimics against A2780 and its taxol-resistant strain (A2780T) cells were screened. 127
The results showed that two of these 36 tRF mimics significantly inhibited the 128 proliferation of the A2780 cells by over 50% at 50 nM (Fig 2b) . Among these tRF 1 0 mimics, tRF-T11 mimic (a double strand RNA with a 22 nt 5'-tRF derived from 130 tRNA His(GUG) as antisense RNA) showed the highest antiproliferative activity against 131 both cell lines. As shown in Fig 2c, the IC 50 value of tRF-T11 mimic for inhibiting the 132 growth of A2780 cells was 31 nM, which is comparable to that of taxol (10.2 nM). 133 Surprisingly, high sensitivity to tRF-T11 mimic was also observed in A2780T cells, 134 corresponding to an IC 50 value of 32 nM, which is 80-fold lower than that of taxol 135 (2600 nM). In addition, no significant cytotoxicity of tRF-T11 mimic to IOSE80 136 normal ovarian surface epithelial cells was observed. Furthermore, the cytotoxicity of 137 tRF-T11 mimic was confirmed by visualizing and tracking fluorescent dye 138 (FAM)-labeled tRF-T11 mimic in A2780 cells. The images shown in Fig 2d indicated  139 that tRF-T11 mimic was efficiently transfected into the cytoplasm of A2780 cells, 140
where they exhibited functions involved in the biological processes, such as 141 suppressing the expression of endogenous targets 19 . These results indicated that 142
Taxus-derived tRFs are promising therapeutic agents for drug-resistant OVCA. 143
The divergent activity of tRF mimics derived from individual tRNAs observed in 144 this study suggested that plant-derived tRFs can exhibit bioactivities in a 1 1 sequence-specific manner in mammalian cells. It has been reported that functionality 146 of exogenous tRFs possibly overlaps that of miRNAs, a characteristic that has been 147 widely documented for endogenous tRFs in both plants and mammalian cells 20,21 . To 148 further identify potential target genes of tRF-T11, we performed an in silico 149 prediction using two independent bioinformatic tools, IntaRNAv2 22 and 150 psRNATarget 23 , followed by differential expression analysis based on the gene 151 expression profiles in normal and tumor ovarian tissue to prioritize the candidate 152 targets. As a result, the top three differentially expressed genes, namely transient 153 receptor potential cation channel subfamily A member 1 (TRPA1), tetraspanin 17 154 (TSPAN17) and secretogranin V (SCG5), with the minimum required energy to 155 hybridize with tRF-T11 at their 3' UTR regions of mRNA, were considered as the 156 potential targets for further experimental validation (Fig 2e) . Among these three genes, 157 TRPA1, a new target recently unveiled by Takahashi et al 24 for cancer therapies, 158 which acts by triggering a noncanonical oxidative stress defense mechanism of tumor 159 suppression, was dramatically downregulated in A2780 cells (by approximately 75%) 160 in a dose-dependent manner by tRF-T11 mimic treatment (Fig 2j, g) , while the 1 2 mRNA levels of the other two targets did not vary significantly (Fig 2f) . Furthermore, 162 a marked decrease of over 50% in the protein expression level of TRPA1 was also 163 observed in A2780 cells treated with tRF-T11 mimic (Fig 2h, i) , which may act as a 164 translational repressor of the TRPA1 gene by acting like a miRNA in human OVCA 165 cells. Indeed, previous reports revealed that TRPA1 overexpression is associated with 166 poor survival probability in patients (Fig 2k) . Unfortunately, no clinical therapeutic 167 drug targeting TRPA1 is available, and our findings provide a novel RNA sequence 168 derived from plant can potently silence human TRPA1. 169
Recently, advances in RNA therapeutics have been facilitated by breakthroughs 170 in pharmaceutical delivery systems, including liposomes, nanoparticles, dendrimers 171 and carbon nanotubes have been shown to provide promising application in vitro and 172 in vivo 25 . To evaluate the antitumor activity in vivo, a histidine-lysine polymer (HKP) 173 nanoparticle system was applied to deliver tRF-T11 mimic to a well-established 174 xenograft mouse model of human OVCA cells. The mass ratio of HKP and tRF-T11 175 mimic was optimized (Fig 3a, b) with an appropriate particle size (164.2 nm) and 176 good dispersion (41.2 mV, Fig 3c) . As shown in Fig 3d to g, compared to vehicle 1 3 control group, tRF-T11 mimic treatment of xenografts for 20 days significantly 178 diminished the tumor growth rate by approximately 50% at a dose of only 177 179 nmol/kg, which is more than 16-fold lower than that of taxol (2928 nmol/kg) required 180 to achieve comparable tumor-suppressive effects without significant adverse impacts 181 on body weight. Compared to those from control mice, the protein expression levels 182 of TRPA1 in the tumors with intratumoral injection of high-dose tRF-T11 mimic 183 exhibited significant reduction (Fig 3h, i) , which is consistent with the western blot 184 results in vitro. Although taxol is a commonly used first-line drug for cancer patients, 185 chemoresistance is usually observed. Since tRF-T11 mimic exhibited comparable 186 tumor suppression efficacy to taxol at a much lower dose, our study may indicate an 187 alternative treatment option. 188
In summary, this study provides the first evidence that plant-derived tRNAs and 189 tRFs from Chinese yew exhibit potent antitumor effects against human OVCA, which 190 will greatly expand our knowledge on the active ingredients in natural sources, and Supplementary Table 3 ) complementary to the target tRNA were mixed 265 with Taxus small RNA and denatured at 95°C for 5 min, followed by incubation at a 266 temperature 5°C lower than the melting temperature (Tm) for 1.5 h. Streptavidin 267 magnetic beads (Beaverbio, China) were then added to the mixture and incubated for 268 30 min at the annealing temperatures. Then, the biotinylated DNA/tRNA-coated 269 beads were separated with a magnet and washed at 40°C. Subsequently, the magnetic 270 beads were resuspended in RNase-free water, and the immobilized tRNA with probes 271 was released by incubation at 65°C for 5 min. 
